CLAIMS

1. Use of a recombinant *Mycobacterium bovis* cell from strain Danish subtype Prague in the manufacture of a vaccine for generating a T helper type 17 (Th17) immune response in a subject in need thereof, wherein the cell is a urease-deficient cell and wherein the cell comprises a recombinant nucleic acid molecule encoding a fusion polypeptide comprising:

(a) a domain from a Mycobacterium polypeptide, which is antigen (Ag) 85B or Ag85A, which is capable of eliciting an immune response, and

(b) a Listeria phagolysosomal escape domain.

2. The use of claim 1, wherein the domain capable of eliciting an immune response is selected from immunogenic peptides or polypeptides from *M*. *bovis* or *M. tuberculosis*.

3. The use of claim 1 or 2, wherein the subject is a mammalian, e.g. human subject.

4. The use of any one of claims 1 to 3, wherein the subject is a Mycobacterium-naïve subject or a subject pre-exposed to Mycobacterium challenge.

5. The use of any one of claims 1-4, wherein the subject has a disorder selected from:

(i) tuberculosis,

(ii) bladder cancer,

(iii) an autoimmune disorder, and

(iv) leprosy.

6. The use of any one of claims 1-5, wherein a Th1 immune response is to be further generated by the vaccine.

7. Use of a recombinant nucleic acid molecule encoding a fusion polypeptide in the manufacture of a vaccine for generating a Th17 immune response in a subject in need thereof, wherein the fusion polypeptide comprising:

(a) a domain from a Mycobacterium polypeptide, which is Ag85B or Ag85A which is capable of eliciting an immune response, and

(b) a Listeria phagolysosomal escape domain.